Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: Biotech/Pharma Business
-
By Jason Derry– For companies interested in entering the Australian biotechnology industry, the Australian Government has created a new website related to biotechnology regulatory requirements. The website, BioRegs Online (www.bioregs.gov.au), was designed to provide easily accessible information to assist companies in devising plans for developing and marketing biotech products. Specifically, BioRegs Online hopes…
-
By Jason Derry — Can the open source problem-solving model used in the software community work in the world of science? The Harvard Business School has published a very interesting interview on this topic (see "Open Source Science: A New Model for Innovation"). In the interview, Karim R. Lakhani, assistant professor at the…
-
By Jason Derry — The Sino-American Biotechnology and Pharmaceutical Professionals Association (SABPA) is a non-profit organization dedicated to fostering licensing and other partnering relationships among biotechnology and pharmaceutical companies and academia in the United States and China. The SABPA hosts numerous networking events, such as dinners and conferences, to facilitate communication between investors,…
-
The Biotechnology Industry Organization (BIO) is hosting the fourth BIO-Asia Partnering Conference in Tokyo on January 29 and 30, 2007. According to BIO’s press release, the conference allows biotech and pharmaceutical companies from Asia, Europe, Australia, and the United States to meet together for the purpose of exploring potential partnering opportunities. The past year’s event…
-
By Jason Derry — NeuroMedix Inc., a biotechnology company seeking therapeutic approaches for treating neuronal diseases, has announced the intent to pursue partners or acquisition possibilities. The company currently has a potential product, Minozac, in pre-clinical studies, and is preparing to submit the Phase I safety application for continuing clinical trial progression. Minozac…
Patent Docs 